An Open-Label, Dose-Finding and Proof of Concept Study of the PD-L1 Probody™ Therapeutic , CX-072, as Monotherapy and in Combination With Yervoy (Ipilimumab) or With Zelboraf (Vemurafenib) in Subjects With Advanced or Recurrent Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered intravenously (IV) as a single agent or in combination with ipilimumab or vemurafenib in adult subjects with advanced or recurrent solid tumors or lymphomas.

CX-072 is a Probody therapeutic directed against PD-L1 (programmed cell death ligand 1). Probody therapeutics are proteolytically-activatable antibodies (Abs) designed to widen the therapeutic index by minimizing drug interaction with normal tissue while retaining anti-tumor activity. Probody therapeutics are masked to attenuate binding to target in healthy tissue but can become unmasked in the tumor microenvironment by tumor-specific protease activity.

Inclusion Criteria:
• Histologically confirmed diagnosis of metastatic or advanced unresectable tumors that progressed on standard therapy
• Agreement to provide mandatory archival tissue or fresh biopsy.

Exclusion Criteria:
• Prior therapy with a chimeric antigen receptor (CAR) T-cell containing regimen.
• History of severe allergic or anaphylactic reactions to human monoclonal antibody therapy or known hypersensitivity to any Probody therapeutic.
• Active or history of uveal, mucosal, or ocular melanoma. Human immunodeficiency virus (HIV) or acquired immune deficiency syndrome (AIDS)-related illness, chronic hepatitis B or C.
• History of or current active autoimmune diseases, including but not limited to inflammatory bowel diseases, rheumatoid arthritis, autoimmune thyroiditis, autoimmune hepatitis, systemic sclerosis, systemic lupus erythematosus, autoimmune vasculitis, autoimmune neuropathies, or type 1 insulin dependent diabetes mellitus.
• History of syndrome or medical condition(s) that requires systemic steroids (> 10 mg daily prednisone equivalents) or immunosuppressive medications.
History of allogeneic tissue/solid organ transplant, prior stem cell or bone marrow transplant.
Phase I
Multiple Tumor Types
Rachel Sanborn, M.D.
CytomX Therapeutics, Inc.
Kim Sutcliffe
  • Providence Cancer Institute Franz Clinic